NCT04237428Unknown不适用
Clinical Study on the Treatment of Relapsed or Refractory CD19 Positive Non-Hodgkin's Lymphoma Patients With Target CD19 Chimeric Antigen Receptor T Cell Infusion
PersonGen BioTherapeutics (Suzhou) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年5月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- BORR
研究概览
简要总结
To evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor T cell infusion in the treatment of relapsed or refractory CD19 positive non-Hodgkin's lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with CD19 positive, relapsed or refractory diffuse large B cell lymphoma and follicular lymphoma who have no effective treatment (such as autologous or allogeneic stem cell transplantation) and have a survival time of several months or less than 2 years must meet all of the following inclusion criteria, and those who do not meet any of the
排除标准
- •can be included:
- •Non Hodgkin's lymphoma was confirmed by histological examination, and one of the following conditions was met:
- •Relapsed and refractory CD19 positive diffuse large B-cell lymphoma: at least after the standard second-line drug treatment, the efficacy evaluation did not reach partial remission or above, or reached partial remission or disease progression after partial remission, or relapsed after complete remission;
- •Relapsed and refractory CD19 positive follicular lymphoma: at least after the standard three-line drug treatment, the efficacy evaluation did not reach partial remission or above, or reached partial remission and disease progress after partial remission, or relapsed after complete remission;
- •Relapsed refractory CD19 positive diffuse large B-cell lymphoma and follicular lymphoma: primary drug resistance; relapse within 1 year after autologous stem cell transplantation only, not affected by other treatment methods previously used; CD20 positive patients should receive corresponding targeted treatment;
- •Age: 18-65 years (including boundary value), gender unlimited;
- •The expected survival time was more than 3 months;
- •ECOG score 0-1 (dose increasing stage), ECoG score 0-2 (expanding group stage);
- •The functions of liver and kidney, heart and lung meet the following requirements:
- •① Creatinine ≤ 1.5 ULN
- •②ALT/AST ≤2.5 ULN；
- •③ Total bilirubin ≤ 1.5 × ULN;
- •④ Baseline oxygen saturation ≥ 92%;
- •⑤ No pericardial effusion was detected by echo;
- •According to Lugano's response standard, there should be at least one measurable tumor focus;
- •Be able to understand the test and have signed the informed consent.
- •Exclusion Criteria:
- •Before screening, they received other chimeric antigen receptor therapy or gene modified cell therapy;
- •Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) is positive and the DNA titer of peripheral blood hepatitis B virus (HBV) is not within the normal reference range; hepatitis C virus (HCV) antibody is positive and peripheral blood HCV RNA is positive; human immunodeficiency virus (HIV) antibody is positive; cytomegalovirus (CMV) DNA is positive; syphilis is positive ;
- •Subjects who were undergoing systemic steroid therapy at the time of screening and who were determined by the investigator to require long-term systemic steroid therapy during the treatment (except for inhalation or local use);
- •In addition to cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical operation, and breast ductal carcinoma in situ after radical operation, malignant tumors other than B-cell acute lymphoblastic leukemia in the first 5 years were screened;
- •Subjects with graft-versus-host disease (GVHD), autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus and Crohn's disease) and / or requiring immunosuppressant within 2 years;
- •Any unstable heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥ grade III) and severe arrhythmia;
- •Any unstable systemic diseases: including but not limited to liver, kidney or metabolic diseases requiring drug treatment;
- •Subjects who received stem cell transplantation within 6 weeks after CD19 car-t infusion were planned;
- •Invasion of central nervous system;
- •Pregnant women and lactating women; and female subjects who plan pregnancy within 1 year after cell transfusion or male subjects whose partners plan pregnancy within 1 year after cell transfusion;
- •According to the judgment of the researchers, it does not conform to the situation of cell preparation;
- •Other researchers think it's not suitable for enrollment.
结局指标
主要结局
BORR
时间窗: 6 months
Best objective response rate
次要结局
- Incidence of AE(2 years)
- Pharmacokinetic parameters(90 Days)
- Overall survival time(through study completion, an average of 5 year)
- Duration of remission after administration(through study completion, an average of 5 year)
- Disease progression free survival(through study completion, an average of 5 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute LeukemiaAcute LeukemiaNCT02822326Guangdong Provincial People's Hospital30
招募中
1 期
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaLymphoma, Large B-Cell, DiffuseLeukemia, B-cellLymphoma, B-CellLeukemiaLeukemia, Lymphocytic, Chronic, B-CellNCT04271410Chongqing Precision Biotech Co., Ltd80
招募中
1 期
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/LymphomaB-cell Acute Lymphoblastic LeukemiaLymphoblastic B-Cell LymphomaNCT05333302Belarusian Research Center for Pediatric Oncology, Hematology and Immunology10
Unknown
早期 1 期
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and VasculitisPOEMS SyndromeVasculitisAutoimmune Hemolytic AnemiaAmyloidosisNCT05263817Zhejiang University75
Unknown
早期 1 期
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus ErythematosusAutoimmune DiseasesSystemic Lupus ErythematosusNCT05030779Zhejiang University9